Watch our latest webinar to learn how the TissueCypher® Barrett’s Esophagus Assay may be an important new precision medicine tool for today’s Barrett’s esophagus expert.


View Webinar


Don't Miss the News from Major GI Conferences in 2019


At DDW in May, Mike Hoerres, CEO, Cernostics was featured in a Roving Reporter Interview from the EndoscopyNow App.

See the full video interview by downloading the app on your mobile device.


App Store




Barrett's Esophagus & Esophageal Cancer

Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn how
View All News
Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus... Read More
Cernostics and Deciphex Announce Strategic Collaboration to Develop AI-Based Histology Diagnostics and Prognostics for Barrett’s Esophagus... Read More
Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE... Read More
01/09/2017 San Francisco, CA
JP Morgan Healthcare Conference
05/06/2017 Chicago, IL
Digestive Disease Week
10/13/2017 Orlando, FL
American College of Gastroenterology
Customer Service

Mon-Fri 9am-5pm (EST)